目的：探讨雷珠单抗联合玻璃体切割术(VT)对PDR患者血清VEGF-A、人基质细胞衍生因子1(SDF-1)表达的影响。

方法：选取2017-01/2018-01本院收治的PDR患者120例，依据随机数字表法分为A组和B组，每组60例，A组给予VT治疗，B组在此基础上给予玻璃体腔注射雷珠单抗治疗，比较两组VT手术情况、并发症及VEGF-A、SDF-1、BCVA、CMT。

结果：两组术后血清VEGF-A、SDF-1水平明显低于术前，且B组明显低于A组(P<0.05)； B组VT手术时间、电凝止血、术中出血及并发症发生率明显低于A组(P<0.05)； 两组术后1d， 3mo BCVA、CMT明显低于术前，且B组明显低于A组(P<0.05)。

结论：雷珠单抗联合VT可有效降低PDR患者血清VEGF-A、SDF-1水平，减少VT创伤及并发症，且可有效改善患者BCVA、CMT。

METHODS: Totally 120 patients with PDR were selected from January 2017 to January 2018 in our hospital, according to the random digital table, they were divided into group A and group B, 60 cases in each group, group A was given VT treatment, group B was given ranibizumab vitreous injection treatment on this basis, the VT operation, complication and VEGF-A, SDF-1, BCVA, CMT were compared between the two groups.

RESULTS: The postoperative serum VEGF-A and SDF-1 levels in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than group A(P<0.05). The VT operation time, electrocoagulation, intraoperative bleeding and complication rate in the group B were significantly lower than those in the group A(P<0.05). The 1d, 3mo postoperative BCVA, CMT in the two groups were significantly lower than those in the preoperative, and the group B was significantly lower than the group A(P<0.05).

CONCLUSION: ranibizumab combined with VT can effectively improve the serum VEGF-A and SDF-1 levels in patients with PDR, it can reduce the trauma and complications of VT, and improve the BCVA and CMT in patient.